Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

The company behind KitKat has launched a protein drink that it claims suppresses appetite in the same way as popular ...

STORY: The battle of the weight loss drugs continues, as Britons paying privately for obesity drugs are increasingly choosing ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...